The US EPA is charged with screening chemicals for their ability to be endocrine disruptors through interaction with the estrogen, androgen and thyroid axes. The agency is exploring the use of highthroughput in vitro assays to use in the Endocrine Disruptor Screening Program (EDSP), potentially as replacements for lower-throughput in vitro and in vivo tests. The first replacement is an integrated computational and experimental model for estrogen receptor (ER) activity, to be used as an alternative to the EDSP Tier 1 in vitro ER binding and transactivation assays and the in vivo uterotrophic bioassay. The ER agonist model uses a set of 16 in vitro assays that incorporate multiple technologies and cell lines and probe multiple points in the ER pathway. Here, we demonstrate that subsets of assays with as few as 4 assays can predict the activity of all 1811 chemicals tested with accuracy equivalent to that of the full 16-assay model. The prediction accuracy against reference chemicals is higher than that of the full chemical set, partly because the larger set contains many chemicals that can cause a variety of types of assay interference There are multiple accurate assay subsets, allowing flexibility in the construction of a multiplexed assay battery. We also discuss the issue of challenging chemicals, i.e. those that can give false positive results in certain assays, and could hence be more problematic when only a few assays are used.
Introduction
There are tens of thousands of man-made chemicals in the environment, and some fraction of these are known or suspected to be xenoestrogens, i.e. they mimic the activity of natural estrogens by binding the estrogen receptor (ER) and triggering downstream gene activation (Safe, 1995) . Such chemicals are potentially endocrine active in vivo and could mimic certain actions of natural estrogens. If sufficiently high exposure to such chemicals results in exposures at target ERs in vivo that overlaps with their potency for the ER, a variety of adverse outcomes at specific life stages may occur, ranging from birth defects to increased rates of cancer progression. . We have developed a computational network model based on a large set of in vitro ER assays (18 in total) , that probe a variety of points in the ER pathway, using both cell-free and cell based assays and a range of detection technologies. The agonist model, which uses data from 16 of the in vitro assays, was validated against in vitro reference chemical activity, as well as reproducible results from guideline-like in vivo uterotrophic studies (Browne et al., 2015; Kleinstreuer et al., 2016) . Note that the original model used 18 assays, which included two that were antagonist-specific. The current work focuses on agonist mode activity because that is of greater concern from an environmental perspective.) Also note that the uterotrophic assay is itself a screening assay, and positive activity does not necessarily imply in vivo adversity. The performance of the ER agonist model was deemed accurate enough that the US EPA has proposed accepting the model results as an alternative to the Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro ER binding and transactivation assays, and the in vivo uterotrophic assay (U.S. EPA, 2015) .
One limitation of the full ER model is the large number of assays used in it, and an obvious question is whether one could achieve equivalent performance with only a subset of the 16 in vitro assays. Within this set of 16 in vitro assays, there are 3 cell-free binding assays, 6 receptor dimerization assays, 2 transactivation assays measuring reporter RNA levels, 2 measuring reporter protein levels, and a cell proliferation assay. The main reason for exploring the use of many in vitro assays, and developing the full ER network model, is that we recognized that all in vitro assays yield false positive and false negative results (Judson et al., 2016) . Additionally, these false activities are not random, but are often due to technologydependent assay interference (Baell and Holloway, 2010; Bruns and Watson, 2012) . A major cause of false positives is activity triggered by cell stress at concentrations approaching where cytotoxicity occurs (Judson et al., 2016) . The full ER network model was developed to help distinguish true activity from false signals. The key output of the model for a chemical was a value referred to as the ER Agonist Area Under the Curve (AUC) score, which is a value from zero to one, normalized with respect to the positive control 17b-Estradiol. A chemical with a score close to 1 is likely to be a strong agonist and one with a score close to zero is unlikely to have any ER agonist activity. The computational model additionally assigned scores to a variety of in vitro assay interference modes, which could be specific to assays or key biological events. An important point about the full model is that it is a so-called ab initio model, meaning that it makes predictions about pathway activity based on measured activity in individual components of the pathway and on the structure of the pathway. In particular, the model did not result from "fitting" data to some simple mathematical form, nor did it employ any machine learning or training data.
Here we explore two issues important to the screening and identification of xenoestrogens: 1) identifying predictive combinations of a minimum number of in vitro assays that perform almost equivalently to the full 16-assay model; and 2) identifying chemicals that are not true ER agonists, but are active in a subset of assays. Using these chemicals in addition to the standard reference chemicals can allow more robust characterization of assay and model performance. We demonstrate that a variety of subsets of in vitro assays perform as well as the full set of 16 assays measuring ER agonist activity. In addition, we find that the in vitro reference chemicals typically used in ER validation studies to date are relatively easy to classify and tend to make the performance of a given in vitro assay subset appear better than it will be for a large collection of chemicals.
Methods
The full ER computational network model and its validation are described elsewhere (Browne et al., 2015; Judson et al., 2015; Kleinstreuer et al., 2016) . We developed 65,535 "subset models" for all combinations of 1e16 in vitro assays. The in vitro assays are listed in Table 1 , and are further described elsewhere . (Note that the Tox21_ERa_LUC_VM7_Agonist assay has previously been annotated as being run in BG1 cells, but this cell line has recently been shown to be of MCF7 origin and renamed VM7Luc4E2 ER TA (see Corrigendum to (Brennan et al., 2016) ). The total database consisted of concentration-response data for the 16 ER in vitro assays (only focusing on agonist activity) for a total of 1811 chemicals. The concentration response data were fit to a Hill model to yield a hit call (yes or no), an AC50 (concentration at half maximum activity) and a maximum activity (top or T). Here T values > 1 were set to 1 (just as in the full model). Assay-chemical pair AUC values were calculated, equal to AUCðchemical; assay i Þ ¼ Àlog 10 ðAC50 i Þ Â T ði 2½1; 16Þ
(1)
Chemical-assay AUC values were scaled so that the median value for the non-zero values for each assay were set to 1. the complete set of chemicals with activity in least one assay, and separately for the reference chemicals (see below). Additionally, we dichotomized the data, calling the chemical "active" if the value of AUC subset ðchemicalÞ was greater than a specified cutoff, and "inactive" otherwise. The value of the cutoff was determined by performing a scan for the 16-assay subset model vs. the full model, and maximizing the balanced accuracy (average of sensitivity and specificity). This yielded a cutoff value of 0.1, which was the same threshold used in the full model. Based on the dichotomized calls, we then calculated sensitivity, specificity and balanced accuracy for each subset model. No separate class of "equivocal" response was used as in Browne et al. (Browne et al., 2015) . Chemicals are classified as "hard to predict" when the difference between the assay AUC (normalized to be in the range of 0e1) and full AUC values is large. For certain analyses, we calculate the average difference between the full AUC and the median assay-chemical AUC. Results for the entire set of 65,535 conditions are given in Supplemental File S2. All computations were carried out using the R programming language, version 3.6.1 (Ihaka and Gentleman, 1996) . All code and input files are available from the authors at the web address: ftp:// newftp.epa.gov/COMPTOX/STAFF/rjudson/publications/ER_assay_ select/.
Here, we evaluate subset models against both the full set of 1811 chemicals with data for the full model, and against a set of reference chemicals. These are chemicals with known ER agonist activity, based on expert review. As we will show in the results section, the reference chemicals tend to be well predicted by many individual assays partially because the assays were optimized against at least some of these reference chemicals. For this study, we used a slightly different set of reference chemicals relative to what was used in the full model paper. We eliminated the in vitro antagonist reference chemicals, because the current analysis focused only on agonist activity, and we included a set of in vivo reference chemicals used in evaluating the full model against the in vivo uterotrophic test (Browne et al., 2015; Kleinstreuer et al., 2016) . The full set of reference chemicals are given in Table 2 with their in vitro and in vivo calls. These lists are publicly available on the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) web site (http://ntp.niehs.nih. gov/pubhealth/evalatm/test-method-evaluations/refchem/index. html).
As subset models were tested, we performed three separate evaluations against the reference chemicals. In the first, we calculated the sensitivity, specificity and balanced accuracy of the subset model relative to the specific classification calls of the full model. Then we calculated the same performance metrics of the subset model relative to the in vitro and in vivo reference chemical classifications from the literature in Table 2 . These can be different, because the predictions of the full model were not always in perfect agreement with the literature reference chemical classifications. In particular, some of the "very weak" in vitro positive reference chemicals were classified as inactive by the full model. (Note that several of these are also inactive in vivo.) In the original paper, we hypothesized that this was due to the maximum testing Zearalenone Active concentration (100 mM) not being high enough to see activity in these very weak xenoestrogens .
Results
Using all 16 in vitro agonist assays, the performance of the subset linear-fit model against the full ER pathway mathematical model, across all 1811 chemicals, is R 2 ¼ 0.96 with an RMSE of 0.071 (Fig. 1) .
The sensitivity, specificity and balanced accuracy (BA) are 0.95, 0.95 and 0.95, respectively. At the low end (AUC close to zero), all of the subset models tend to over-predict the AUC values of the full ER network model because the full model moves the score into specific interference ("pseudo-receptor") modes, and out of the agonist (or antagonist) mode . For chemicals with a full model AUC above the cutoff, the confidence intervals around the full and subset models mostly overlap with the diagonal (red points). Confidence intervals are calculated using a bootstrap approach described elsewhere (Watt and Judson, in preparation) .
The relatively large confidence intervals support the use of a simple additive linear approach (Eq. (2)) to explore multiple variations of subset models in a computationally efficient way.
The performance metrics for all subset models (combinations of assays) with a minimum BA >0.92 are given in Supplemental File S3. The "minimum BA" is the minimum value for the BA for: in vitro literature-based reference chemicals , in vivo literature-based reference chemicals , all reference chemicals vs. the full model, and all chemicals vs. the full model. The threshold of 0.92 was selected because it is only slightly below the maximum "minimum BA" for all 16 assays (0.94), but allows for an exploration of a diverse set of models with a range of assay subsets. There are 518 models (out of a total of 65,535) with a minimum BA>0.92, with the number of assays ranging from 3 to 12. Fig. 2 shows the BA for all models as a function of the number of in vitro assays used. From examining the top panel for BA for all chemicals, one can see that it is possible to achieve 96% BA (all chemicals vs. the full model) for certain combinations of 7 or more in vitro assays. This performance is above that for the model with all 16 assays. (This is likely because the model is being forced to fit more assay noise.) By looking at the bottom panel, one can see that the performance for just the in vitro reference chemicals is better on average, and in fact shows that there are sets of as few as 4 assays that correctly classify all of the in vitro reference chemicals, relative to their classification in the full model. However, as we explore below, subset models that optimize one metric (e.g. classification of the reference chemicals vs. the full model), may have suboptimal (and potentially very poor) performance on other metrics, such as classification of non-reference chemicals, or classification of reference chemicals against the literature results (Browne et al., 2015; Kleinstreuer et al., 2016) . Table 3 gives the performance metrics for the best model for each number of assays from 1 to 16, where "best" means the subset model with the highest minimum-BA, as defined above. (Note that there were some ties for the best value, so only one example is given here. Values for all models are given in Supplemental File S2.) We see subset models reaching the highest value of 0.94 with as few as 4 assays (in this case the human cell free binding assay NVS_NR_hER, the OT protein dimerization assay OT_ER_ER-aERb_1440, the ATG TRANS reporter assay ATG_ERa_TRANS, and the proliferation assay, ACEA_T47D_80hr_Positive). Other combinations with more assays achieve the same level of accuracy, but these typically add to this first set of 4 assays, although the selection of which protein complementation assay(s) are used can vary. Optimal performance drops off as more than 12 assays are used. Notice that the weights of certain assays (usually from OT) are negative, indicating that they are being used to pull down the AUC values, and essentially to compensate for over-sensitivity in other assays. Fig. 3 graphically shows this increase and then decrease in performance with the number of assays included. By comparing Figs. 2 and 3, we see that some subset models can achieve high BA against the full model, but these models may not be as good overall at simultaneously achieving high accuracy against all of the performance metrics. Table 4 gives the frequency for selection of the assays in the 512 subset models with minimum BA >0.92. The ATG TRANS assays is selected in almost all models (as it is selected in all of the best subset models in Table 3 ). This assay tends to have a high sensitivity with a lower specificity , but is likely included in the subset models to maximize the combined sensitivity. The inclusion of other less sensitive but more specific assays then helps to compensate by bringing the model's overall rate of false positives and false negatives down. The corresponding ATG CIS assay is rarely used, likely because it has similarly high sensitivity and low specificity characteristics, but to a lesser extent. The ACEA cell proliferation assay is the second most often used. As with the ATG assays, it tends to be highly sensitive, with a low specificity. The next three assays in order are the human, mouse and bovine cell-free binding assays. These typically have a lower sensitivity, missing many weak compounds, but are very specific (few false positives). The OT protein complementation assays are all used at intermediate frequencies. These assays are highly correlated, so that subset models with one of these assays will demonstrate similar performance as with any of the others. The 2-h OT chromatin binding assay (OT_ERa_EREGFP_0120) is almost never selected, perhaps because activity has not stabilized at this short time point. The Tox21 beta lactamase transactivation assay is one of the less frequently selected assays, while the Tox21 VM7 luciferase assay is more frequently used due to its increased sensitivity.
The principal take-home message from the preceding analysis is that there are a variety of in vitro assay subsets that can be used to accurately classify chemicals for ER agonist activity. However, none of the models gives exactly the same classification as the full model, so it is worth exploring the issue of what types of chemicals yield false positive results in these assays and models. Note that the false negative reference chemicals in the full model (and in the subset models) are almost all due to the limited upper testing concentration (~100 mM). Here, we focus on "subset false positive chemicals", which are ones where the subset model indicates that the chemical is positive for estrogenicity, while the full model indicates that it is negative. As fewer and fewer assays are included in a model, a strong false positive signal in one assay can lead to a positive overall call, one that would be diluted if more (presumably negative) assays were included. Here, we calculate a metric which is the difference between the largest individual assay AUC (Eq. (1)) and the full model AUC. Fig. 4 shows a heatmap of all chemicals with a difference of 0.35 or greater, as an illustration. The top three chemicals are selective estrogen receptor modulators that are usually functionally classified as ER antagonists. These have high full-model antagonist AUC scores , and are expected to have significant activity in the upstream assays in the pathway (binding, protein dimerization, chromatin binding), but limited to no activity in the downstream agonist assays (transactivation, proliferation) , which is what is seen here. In the second block are several progesterone or glucocorticoid-activating chemicals, active mostly in the ACEA cell proliferation assay. This assay, run in T47D cells, is known to be sensitive to these classes of chemicals independent of the estrogen receptor. A number of the remaining chemicals are detergents or solvents which may be activating the in vitro assays through a cellstress or technology interference pathways. Most of these "false positive" chemicals are principally active in the ATG assays, as Fig. 2 . Boxplots of balanced accuracy (vs. the full model, using a cutoff of 0.1) for all subset models as a function of the number of in vitro assays used, (A) all chemicals and (B) in vitro reference chemicals. The bar in the middle of the box is the median value, the box indicates the middle two quantiles, the whiskers the 95% level, and points outliers beyond 95% of the distribution. The horizontal line is set at 0.96, the maximum BA seen for any model across all chemicals. Statistics for all individual models are given in Supplemental File S2.
Table 3
Best models for each number of assays. Columns (1, 2, 3 … 16) indicate the number of assays. BA (balanced accuracy), sensitivity and specificity values are measured relative to the classification of all chemicals in the full model. observed previously . One hypothesis about these chemicals is that they are actually estrogenic, but only after bioactivation. The ATG assays are run in a sub-strain of HepG2 cells that was selected for increased CYP activity.
Discussion
In this paper, we have described an approach for selecting a minimum battery of ER assays to use in classifying the estrogenic agonist activity of a chemical. We started with a set of 16 assays covering multiple points in the estrogen signaling pathway, which had been combined using a mathematical model that was used to distinguish true agonist or antagonist activity from assay or technology-specific assay interference activity , and was validated as an alternative to the rodent uterotrophic assay (Browne et al., 2015) . Here, we showed that one can use a simple linear model that combines individual chemical-assay AUC values to achieve comparable performance for agonist activity. The chemical-assay AUC value is a combination of potency and efficacy (Eq. (1)). Using this simple linear model, we evaluated the accuracy of all combinations of 1e16 assays (65,535 in total) against the results of the full model, and well-studied in vitro and in vivo reference chemicals.
From this analysis, we found that there were many combinations of subsets of assays that performed at levels comparable to the full 16-assay model. Interestingly, the performance against just the in vitro reference chemicals was often (but not always) higher than against either the in vivo reference chemicals, or against the complete set of~1800 chemicals evaluated in the full model. This indicates that a battery evaluated (or validated) against only the standard reference chemicals may overstate the true accuracy of the model. This is due to the fact that there are certain chemicals that will be positive in only one assay or technology, either through assay interference (Baell and Holloway, 2010; Bruns and Watson, 2012) , or through true activity that is only captured by that assay (e.g. through metabolic activation which does not occur in most of the current in vitro assays). The assay-specific false positive activity is a key factor determining the domain of applicability of the assay, which is one aspect of standard assay validation practice (ICCVAM, 1997; Hartung et al., 2004; Judson et al., 2013) . In general, the narrower the set of chemicals used to evaluate an assay, the narrower will be the domain of applicability. We analyzed the types of chemicals that show significant differences between the full model AUC and the AUC for individual assays. This analysis showed that such chemicals include antagonists (which are appropriately active in a subset of the agonist assays), chemicals such as detergents, which are likely causing false activity through cell stress in certain cell types (Judson et al., 2016) , and chemicals only active in metabolically competent cells.
Note that some of the false positive (and false negative) activity in the data set used here is not "true", i.e. some of it is due to experimental variability at the time the assays were run. However, by using data from such a large set of chemicals, such noise should be overwhelmed by the larger signal.
Based on these results, we can conclude that one could use any one of multiple subset models to accurately predict the estrogenic potential of a chemical. There are subsets that include as few as 4 of the original 16 assays that simultaneously have acceptable performance against the full model, and the in vitro and in vivo reference chemicals. There are other subsets that have good performance against just the in vitro reference chemicals, but perform poorly against the full set, and these subsets would not be acceptable substitutes. The acceptable subsets all have assays that probe diverse points in the ER pathway, and use diverse assay reporting technologies and cell types. Note that there are subsets of assays that are more or less sensitive or specific, so that one could tune a battery, for instance to be more sensitive and less specific, and then follow-up actives with other more specific tests. What we have described here are scientific findings that could be used for detecting in vitro ER activity, regardless of the regulatory context. To date, the US EPA has not issued an opinion or guidance on using the subset models in a regulatory context.
Because we have tested a large and diverse library of chemicals in this set of 16 assays, we can characterize the types of chemicals that give false positive results, and hence can help characterize the domain of applicability for the assays. One could construct similar batteries using assays that are not included in the 16 used here, but our results suggest that to evaluate performance, one would need to test more chemicals than just the standard in vitro reference set. There is not a universal set of assay interference chemicals, but there are likely ones that yield false positive results in many assays using the same cell type or readout. Therefore, by mining available data for assays similar to a new one that is proposed for inclusion in an ER battery, one could develop a set of chemicals to help characterize that assays domain of applicability.
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